Article

Shaji Kumar on Later Lines of Treatment for Myeloma

Author(s):

There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.

Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, provides an overview of later lines of therapy for patients with multiple myeloma.

There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.
Image of Dr. Kumar.
Photo of a woman with shoulder-length black hair wearing a blazer
Image of a woman wearing a headband and glasses
Image of man.
Image of doctor.
CURE spoke with Andy Guinigundo to discuss the role that biomarkers play for patients with breast cancer.
Related Content